Behcet Syndrome Clinical Trial
Official title:
The Effect of Behcet's Disease on Cerebrovascular Circulation
Assessment of structural changes that occur in large extracranial and intracranial arteries in patients with Behcet's disease
Patients will be selected from Rheumatology and Rehabilitation inpatient and outpatient clinics in Assiute University Hospital Patients under 16 years old, patients with hyperlipidemia, hypertension, diabetes mellitus and all other risk factors affecting blood vessel intimal thickness will be excluded from the research. All patients and control groups underwent a complete extracranial and intracranial ultrasound assessment by 2 experienced neurovascular sonographers .The ultrasound examination was done at the Neurovascular Ultrasound Laboratory in the Neurology department, Assiut University hospitals using a color-coded duplex ultrasound device Philips HD5 (Philips Medical Systems, Nederland B.V.) for the carotid and vertebral arteries and for the intracranial arteries. Intimal medial thickness (IMT) of the common carotid artery (CCA), peak systolic velocities (PSVs) and end diastolic velocities (EDVs) were measured in the common, internal, and external carotid arteries (CCA, ICA, ECA) with L 3-12 MHz linear transducer probe and when stenosis was detected the velocities were measured at the maximally stenotic area. The intracranial arteries were evaluated in all patients with transcranial color-coded duplexsonography (TCCS) with the use of a low-frequency (2- to 5-MHz) phased-array probe through the transtemporal acoustic bone window. The middle cerebral artery (MCA), intracranial segment of vertebral artery (V4)and basilar artery (BA) were examined. Peak systolic velocity (PSV) and flow direction (antegrade or reversed) used for the diagnosis of any intracranial atherosclerotic disease (ICAD). The findings and the atherosclerotic changes in the extracranial and intracranial vessels were interpreted according to the internationally published data Data will be analyzed using the computer program SPSS ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274648 -
Dietary Interventions and Butyrate Production in Behçet's Patients
|
N/A | |
Terminated |
NCT01693653 -
Tocilizumab for the Treatment of Behcet's Syndrome
|
Phase 2 | |
Completed |
NCT04961463 -
Evaluation of the Psychoeducation Program Given to Behcet's Patients in the Context of the Roy Adaptation Model
|
N/A | |
Completed |
NCT05142995 -
Sleep Related Breathing Disorders, Anxiety, Depression and Quality of Life Assessment in Behcet's Disease
|
||
Recruiting |
NCT00931957 -
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
|
N/A | |
Completed |
NCT03514056 -
Frequency of Fibromyalgia in Behcet Disease
|
||
Not yet recruiting |
NCT03771768 -
Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease
|
N/A | |
Terminated |
NCT03554161 -
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Completed |
NCT03264391 -
Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
|
||
Completed |
NCT04386824 -
Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
|
||
Completed |
NCT03962335 -
Gut Microbiota and Behcet's Syndrome: a Dietary Intervention Trial (MAMBA Study)
|
N/A | |
Completed |
NCT01532570 -
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
|
Phase 3 | |
Not yet recruiting |
NCT04186559 -
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
|
Phase 2 | |
Terminated |
NCT04218565 -
Golimumab for the Treatment of Refractory Behcet's Uveitis
|
Phase 2 | |
Not yet recruiting |
NCT03747354 -
Assessment of Disease Activity in Behcet by Complete Blood Count
|
N/A | |
Recruiting |
NCT05200715 -
AutoInflammatory Disease Alliance Registry (AIDA)
|
||
Completed |
NCT05098678 -
Zinc Supplementation and Behçet's Syndrome
|
N/A | |
Completed |
NCT00866359 -
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
|
Phase 2 | |
Completed |
NCT00483184 -
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
|
Phase 2 | |
Completed |
NCT05032248 -
Uses of Tacrolimus in Behcet Disease
|
N/A |